Stock Analysis

Elekta (STO:EKTA B) Is Due To Pay A Dividend Of SEK1.20

Elekta AB (publ)'s (STO:EKTA B) investors are due to receive a payment of SEK1.20 per share on 12th of September. This means the annual payment is 3.5% of the current stock price, which is above the average for the industry.

See our latest analysis for Elekta

Advertisement

Elekta's Payment Has Solid Earnings Coverage

If the payments aren't sustainable, a high yield for a few years won't matter that much. Prior to this announcement, Elekta's dividend was making up a very large proportion of earnings and perhaps more concerning was that it was 112% of cash flows. Paying out such a high proportion of cash flows certainly exposes the company to cutting the dividend if cash flows were to reduce.

Looking forward, earnings per share is forecast to rise by 71.3% over the next year. If the dividend continues along recent trends, we estimate the payout ratio will be 68%, which is in the range that makes us comfortable with the sustainability of the dividend.

historic-dividend
OM:EKTA B Historic Dividend August 15th 2024

Dividend Volatility

While the company has been paying a dividend for a long time, it has cut the dividend at least once in the last 10 years. The annual payment during the last 10 years was SEK1.50 in 2014, and the most recent fiscal year payment was SEK2.40. This means that it has been growing its distributions at 4.8% per annum over that time. We're glad to see the dividend has risen, but with a limited rate of growth and fluctuations in the payments the total shareholder return may be limited.

Dividend Growth May Be Hard To Achieve

Growing earnings per share could be a mitigating factor when considering the past fluctuations in the dividend. Although it's important to note that Elekta's earnings per share has basically not grown from where it was five years ago, which could erode the purchasing power of the dividend over time. Slow growth and a high payout ratio could mean that Elekta has maxed out the amount that it has been able to pay to shareholders. When a company prefers to pay out cash to its shareholders instead of reinvesting it, this can often say a lot about that company's dividend prospects.

In Summary

Overall, we don't think this company makes a great dividend stock, even though the dividend wasn't cut this year. While the low payout ratio is a redeeming feature, this is offset by the minimal cash to cover the payments. We would probably look elsewhere for an income investment.

Investors generally tend to favour companies with a consistent, stable dividend policy as opposed to those operating an irregular one. At the same time, there are other factors our readers should be conscious of before pouring capital into a stock. For example, we've picked out 1 warning sign for Elekta that investors should know about before committing capital to this stock. Looking for more high-yielding dividend ideas? Try our collection of strong dividend payers.

Valuation is complex, but we're here to simplify it.

Discover if Elekta might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.

Access Free Analysis

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

About OM:EKTA B

Elekta

A medical technology company, provides clinical solutions for treating cancer and brain disorders in the Americas, Europe, the Middle East, Africa, and the Asia Pacific.

Excellent balance sheet with reasonable growth potential and pays a dividend.

Advertisement

Updated Narratives

BE
Bejgal
MNSO logo
Bejgal on MINISO Group Holding ·

MINISO's fair value is projected at 26.69 with an anticipated PE ratio shift of 20x

Fair Value:US$26.6928.0% undervalued
44 users have followed this narrative
3 users have commented on this narrative
0 users have liked this narrative
TI
TickerTickle
ORCL logo
TickerTickle on Oracle ·

The Quiet Giant That Became AI’s Power Grid

Fair Value:US$389.8149.5% undervalued
6 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
AU
AuCA
NLBR logo
AuCA on Nova Ljubljanska Banka d.d ·

Nova Ljubljanska Banka d.d will expect a 11.2% revenue boost driving future growth

Fair Value:€20916.3% undervalued
23 users have followed this narrative
3 users have commented on this narrative
0 users have liked this narrative

Popular Narratives

OS
oscargarcia
GOOGL logo
oscargarcia on Alphabet ·

The company that turned a verb into a global necessity and basically runs the modern internet, digital ads, smartphones, maps, and AI.

Fair Value:US$3404.9% undervalued
134 users have followed this narrative
6 users have commented on this narrative
18 users have liked this narrative
TH
TheWallstreetKing
MVIS logo
TheWallstreetKing on MicroVision ·

MicroVision will explode future revenue by 380.37% with a vision towards success

Fair Value:US$6098.4% undervalued
82 users have followed this narrative
10 users have commented on this narrative
18 users have liked this narrative
AN
AnalystConsensusTarget
NVDA logo
AnalystConsensusTarget on NVIDIA ·

NVDA: Expanding AI Demand Will Drive Major Data Center Investments Through 2026

Fair Value:US$232.7923.6% undervalued
919 users have followed this narrative
5 users have commented on this narrative
21 users have liked this narrative